<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320021</url>
  </required_header>
  <id_info>
    <org_study_id>PYR-205/207</org_study_id>
    <secondary_id>PYR-205</secondary_id>
    <secondary_id>PYR-207</secondary_id>
    <nct_id>NCT00320021</nct_id>
  </id_info>
  <brief_title>Effect of Pyridorin in Patients With Diabetic Nephropathy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Escalating Dose, Pilot Study to Evaluate the Safety, Tolerability and Biologic Activity of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioStratum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioStratum</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety, tolerability and efficacy of
      Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients
      with diabetic kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date>September 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Creatinine from baseline to week 26</measure>
  </primary_outcome>
  <enrollment>80</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridorin (pyridoxamine dihydrochloride)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females (non-pregnant and non-lactating) between 18 and 70 years of age with
             type 1 or type 2 diabetes

          -  Sitting blood pressure of &lt;=170/100 mm Hg at weeks -2 and -1

          -  Hemoglobin A1C &lt;=12% at week -2

          -  Patients with diagnosis of diabetic nephropathy as defined by

               1. Serum Creatinine &lt;=2.0 mg/dL at weeks -2 and -1 (PYR-205) Serum Creatinine &gt;2.0
                  mg/dL but &lt;=3.5 mg/dL at weeks -2 and -1 (PYR-207)

               2. Urinary albumin excretion &gt;=300 mg/24 hours at week -2

               3. No other known or suspected etiology for nephropathy

          -  Voluntary written consent to participate in this study

        Exclusion Criteria:

          -  History of allergic or adverse response to any B vitamin

          -  History of major cardiovascular or cerebrovascular events

          -  History of cancer except adequately treated basal or squamous cell carcinoma of the
             skin

          -  History of diabetic ketoacidosis

          -  Autoimmune diseases

          -  History of significant peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten P Degenhardt, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>BioStratum, Inc.</affiliation>
  </overall_official>
  <verification_date>April 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>April 27, 2006</last_update_submitted>
  <last_update_submitted_qc>April 27, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2006</last_update_posted>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Advanced Glycation Endproduct Inhibitor</keyword>
  <keyword>Pyridorin</keyword>
  <keyword>Pyridoxamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

